Literature DB >> 8130023

Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina.

E Gurfinkel1, R Altman, A Scazziota, J Rouvier, B Mautner.   

Abstract

OBJECTIVE: To investigate whether plaque rupture and thrombosis have a role in silent ischaemia as well as in unstable angina.
DESIGN: Prospective analysis of the results of haemostatic diagnostic tests at the moment of developing silent ischaemia at rest.
SETTING: Coronary care unit. PATIENTS: 22 patients with acute myocardial infarction, 12 patients with symptomatic angina (unstable angina), and 10 normal volunteers (control group).
INTERVENTIONS: Continuous cardiac monitoring detected 15 asymptomatic episodes (silent ischaemia) in 6 patients with unstable angina. Blood samples were obtained at admission and when an asymptomatic alteration was detected and 10 minutes later. MAIN OUTCOME MEASURES: Comparisons of concentrations of tissue plasminogen activator, urokinase type plasminogen activator, tissue plasminogen activator inhibitor-1, cross-linked fibrin degradation products, von Willebrand factor, and thrombin-antithrombin III complexes in patients and controls at admission; same comparisons in patients with silent ischaemia at the start of an episode and 10 minutes later.
RESULTS: Tissue plasminogen activator concentrations were raised at admission in patients with acute myocardial infarction (mean (SD) 14.2 (6) ng/ml) and in patients with unstable angina (10.1 (2.5) ng/ml) in comparison with controls (5.1 (2.7) ng/ml, p < 0.01 and < 0.05 respectively). There was no differences between the two groups of patients, however. Similar results were observed at the start of a silent ischaemic episode (9.8 (1.9) ng/ml) and 10 minutes later (10.5 (2.9) ng/ml) compared with controls (p < 0.05). Tissue plasminogen activator inhibitor-1 concentrations were raised in patients with acute myocardial infarction (45.1 (15) ng/ml) compared with volunteers (20.6 (16) ng/ml, p < 0.01). In patients with silent ischaemia tissue plasminogen activator inhibitor-1 concentrations were slightly but not significantly increased. Concentrations of cross-linked fibrin degradation products (D dimer) increased during unstable angina (2150 (350) ng/ml) and silent ischaemia (2270 (450) ng/ml) compared with the concentrations in volunteers (340 (80) ng/ml) and patients with acute myocardial infarction (310 (120) ng/ml; p < 0.01).
CONCLUSIONS: The results suggest that thrombosis mediates the pathophysiological mechanisms of silent ischaemia and unstable angina.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8130023      PMCID: PMC483635          DOI: 10.1136/hrt.71.2.151

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  18 in total

1.  Letter: A method for assaying von Willebrand factor (ristocetin cofactor).

Authors:  D E Macfarlane; J Stibbe; E P Kirby; M B Zucker; R A Grant; J McPherson
Journal:  Thromb Diath Haemorrh       Date:  1975-09-30

2.  Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques.

Authors:  S D Gertz; W C Roberts
Journal:  Am J Cardiol       Date:  1990-12-01       Impact factor: 2.778

3.  Dynamic thrombosis and thrombolysis. Role of antithrombins.

Authors:  J H Chesebro; V Fuster
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

4.  Thrombosis in unstable angina.

Authors:  J H Chesebro; V Fuster
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

5.  Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm.

Authors:  R J Myerburg; K M Kessler; S M Mallon; M M Cox; E deMarchena; A Interian; A Castellanos
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  Unstable angina: role of silent ischemia and total ischemic time (silent plus painful ischemia), a 6-year follow-up.

Authors:  F Romeo; G M Rosano; E Martuscelli; A Valente; A Reale
Journal:  J Am Coll Cardiol       Date:  1992-05       Impact factor: 24.094

8.  Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease.

Authors:  A M Zeiher; V Schächinger; S H Weitzel; H Wollschläger; H Just
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

9.  Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium.

Authors:  S Munkvad; J Jespersen; J Gram; C Kluft
Journal:  J Intern Med       Date:  1990-10       Impact factor: 8.989

10.  Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.

Authors:  A Zalewski; Y Shi; D Nardone; B Bravette; P Weinstock; D Fischman; P Wilson; S Goldberg; D C Levin; T D Bjornsson
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

View more
  4 in total

1.  Low molecular weight heparins (enoxaparin) in the management of unstable angina: the TIMI studies. Thrombolysis in Myocardial Infarction.

Authors:  E Gurfinkel; B M Scirica
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

2.  Current treatment and future prospects for the management of acute coronary syndromes: consensus recommendations of the 1997 ushuaia conference, tierra del fuego, Argentina.

Authors:  E Gurfinkel
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2007-08-29

4.  Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.

Authors:  Aline Tatiane Toneto; Luiz Alberto Ferreira Ramos; Emilianne Miguel Salomão; Rebeka Tomasin; Miguel Arcanjo Aereas; Maria Cristina Cintra Gomes-Marcondes
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-24       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.